The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate

Gary Ventolini, Janice Duke, William Po, Sheela Barhan, Debbie Rhea, Cheryl Desch, Niki Istwan, Gary Stanziano

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

OBJECTIVE: To examine the impact of maternal prepregnancy body mass index (BMI) on rates of recurrent preterm delivery (PTD) in women receiving 17α-hydroxyprogesterone caproate (17P) prophylaxis. STUDY DESIGN: The study population was identified from a large perinatal database containing prospectively collected information from women at high risk for PTD. We included patients with a current singleton pregnancy and a history of PTD who received weekly nursing visits and 17P 250 mg intramuscular injections beginning at 16.0 to 20.9 weeks' gestation. The data were stratified by number of prior PTDs (1 or > 1) and maternal prepregnancy BMI (lean, normal, overweight and obese). Primary study outcomes included the rates of recurrent PTD at < 35 and 32 weeks' gestation, and pregnancy loss at < 24 weeks' gestation. RESULTS: Delivery outcomes for 606 women receiving 17P were analyzed. There were no significant differences found in the incidence of preterm labor, the rates of recurrent PTD or pregnancy loss at < 35, 32 or 24 weeks between the BMI groups. CONCLUSION: Maternal prepregnancy BMI does not appear to influence the rates of recurrent PTD in women with singleton gestation receiving 17P prophylaxis. Larger studies are needed to confirm our findings.

Original languageEnglish
Pages (from-to)667-671
Number of pages5
JournalJournal of Reproductive Medicine for the Obstetrician and Gynecologist
Volume53
Issue number9
StatePublished - 1 Sep 2008

Fingerprint

Mothers
Pregnancy
Body Mass Index
17-alpha-Hydroxyprogesterone
Reproductive History
Premature Obstetric Labor
Intramuscular Injections
17-alpha-hydroxy-progesterone caproate
Nursing
Outcome Assessment (Health Care)
Databases
Incidence
Population

Keywords

  • 17α-hydroxy-progesterone
  • Body mass index
  • Premature labor

Cite this

Ventolini, Gary ; Duke, Janice ; Po, William ; Barhan, Sheela ; Rhea, Debbie ; Desch, Cheryl ; Istwan, Niki ; Stanziano, Gary. / The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate. In: Journal of Reproductive Medicine for the Obstetrician and Gynecologist. 2008 ; Vol. 53, No. 9. pp. 667-671.
@article{2c7908db6d0640529bd66d3d78875579,
title = "The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate",
abstract = "OBJECTIVE: To examine the impact of maternal prepregnancy body mass index (BMI) on rates of recurrent preterm delivery (PTD) in women receiving 17α-hydroxyprogesterone caproate (17P) prophylaxis. STUDY DESIGN: The study population was identified from a large perinatal database containing prospectively collected information from women at high risk for PTD. We included patients with a current singleton pregnancy and a history of PTD who received weekly nursing visits and 17P 250 mg intramuscular injections beginning at 16.0 to 20.9 weeks' gestation. The data were stratified by number of prior PTDs (1 or > 1) and maternal prepregnancy BMI (lean, normal, overweight and obese). Primary study outcomes included the rates of recurrent PTD at < 35 and 32 weeks' gestation, and pregnancy loss at < 24 weeks' gestation. RESULTS: Delivery outcomes for 606 women receiving 17P were analyzed. There were no significant differences found in the incidence of preterm labor, the rates of recurrent PTD or pregnancy loss at < 35, 32 or 24 weeks between the BMI groups. CONCLUSION: Maternal prepregnancy BMI does not appear to influence the rates of recurrent PTD in women with singleton gestation receiving 17P prophylaxis. Larger studies are needed to confirm our findings.",
keywords = "17α-hydroxy-progesterone, Body mass index, Premature labor",
author = "Gary Ventolini and Janice Duke and William Po and Sheela Barhan and Debbie Rhea and Cheryl Desch and Niki Istwan and Gary Stanziano",
year = "2008",
month = "9",
day = "1",
language = "English",
volume = "53",
pages = "667--671",
journal = "Journal of Reproductive Medicine for the Obstetrician and Gynecologist",
issn = "0024-7758",
publisher = "Donna Kessel",
number = "9",

}

Ventolini, G, Duke, J, Po, W, Barhan, S, Rhea, D, Desch, C, Istwan, N & Stanziano, G 2008, 'The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate', Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 53, no. 9, pp. 667-671.

The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate. / Ventolini, Gary; Duke, Janice; Po, William; Barhan, Sheela; Rhea, Debbie; Desch, Cheryl; Istwan, Niki; Stanziano, Gary.

In: Journal of Reproductive Medicine for the Obstetrician and Gynecologist, Vol. 53, No. 9, 01.09.2008, p. 667-671.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate

AU - Ventolini, Gary

AU - Duke, Janice

AU - Po, William

AU - Barhan, Sheela

AU - Rhea, Debbie

AU - Desch, Cheryl

AU - Istwan, Niki

AU - Stanziano, Gary

PY - 2008/9/1

Y1 - 2008/9/1

N2 - OBJECTIVE: To examine the impact of maternal prepregnancy body mass index (BMI) on rates of recurrent preterm delivery (PTD) in women receiving 17α-hydroxyprogesterone caproate (17P) prophylaxis. STUDY DESIGN: The study population was identified from a large perinatal database containing prospectively collected information from women at high risk for PTD. We included patients with a current singleton pregnancy and a history of PTD who received weekly nursing visits and 17P 250 mg intramuscular injections beginning at 16.0 to 20.9 weeks' gestation. The data were stratified by number of prior PTDs (1 or > 1) and maternal prepregnancy BMI (lean, normal, overweight and obese). Primary study outcomes included the rates of recurrent PTD at < 35 and 32 weeks' gestation, and pregnancy loss at < 24 weeks' gestation. RESULTS: Delivery outcomes for 606 women receiving 17P were analyzed. There were no significant differences found in the incidence of preterm labor, the rates of recurrent PTD or pregnancy loss at < 35, 32 or 24 weeks between the BMI groups. CONCLUSION: Maternal prepregnancy BMI does not appear to influence the rates of recurrent PTD in women with singleton gestation receiving 17P prophylaxis. Larger studies are needed to confirm our findings.

AB - OBJECTIVE: To examine the impact of maternal prepregnancy body mass index (BMI) on rates of recurrent preterm delivery (PTD) in women receiving 17α-hydroxyprogesterone caproate (17P) prophylaxis. STUDY DESIGN: The study population was identified from a large perinatal database containing prospectively collected information from women at high risk for PTD. We included patients with a current singleton pregnancy and a history of PTD who received weekly nursing visits and 17P 250 mg intramuscular injections beginning at 16.0 to 20.9 weeks' gestation. The data were stratified by number of prior PTDs (1 or > 1) and maternal prepregnancy BMI (lean, normal, overweight and obese). Primary study outcomes included the rates of recurrent PTD at < 35 and 32 weeks' gestation, and pregnancy loss at < 24 weeks' gestation. RESULTS: Delivery outcomes for 606 women receiving 17P were analyzed. There were no significant differences found in the incidence of preterm labor, the rates of recurrent PTD or pregnancy loss at < 35, 32 or 24 weeks between the BMI groups. CONCLUSION: Maternal prepregnancy BMI does not appear to influence the rates of recurrent PTD in women with singleton gestation receiving 17P prophylaxis. Larger studies are needed to confirm our findings.

KW - 17α-hydroxy-progesterone

KW - Body mass index

KW - Premature labor

UR - http://www.scopus.com/inward/record.url?scp=53549097629&partnerID=8YFLogxK

M3 - Article

C2 - 18839818

AN - SCOPUS:53549097629

VL - 53

SP - 667

EP - 671

JO - Journal of Reproductive Medicine for the Obstetrician and Gynecologist

JF - Journal of Reproductive Medicine for the Obstetrician and Gynecologist

SN - 0024-7758

IS - 9

ER -